Year in Review: Updates in Treating Myelofibrosis : Episode 12
Opinion
Video
Emerging Treatments for Myelofibrosis
Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.
EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF
EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2
EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1
EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib
EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034
EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001
EP: 7.Future Directions in Combination Therapies for Myelofibrosis
EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF
EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib
EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF
EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis
Now Viewing
EP: 12.Emerging Treatments for Myelofibrosis
Related Videos
Related Content
